Ticker: GILD

Gilead Sciences

Pharma Healthcare Drug Manufacturers - General

Price 156.04

Reco Buy Potential 76 Risk 36 Updated 2026-10-25

Official website

Forecast impact

positive

Target +18.6% target fill 84.3%

Reaction D5 pending · D10 pending fresh confirmed · market trust

Impact Potential +6 · Risk -3 valid until 2026-11-22

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Gilead Sciences is a biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Its core products include antiviral therapies for HIV, hepatitis B, hepatitis C, and influenza, as well as treatments for cancer and inflammatory diseases. Major business segments consist of antiviral and oncology products, with primary revenue sources stemming from sales of these therapies. The company is recognized for its contributions to public health through its advanced drug formulations and research initiatives.

Investment Profile

Gilead Sciences presents a profile more aligned with dividend investors due to its consistent dividend yield. The stock may appeal to those seeking income rather than aggressive growth, given its established market presence and product portfolio. However, recent revenue declines suggest caution for value investors. The stock may suit a balanced approach, considering its potential for moderate returns alongside dividend income.

Category: Pharma Sector: Healthcare Industry: Drug Manufacturers - General Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-10-26

EPS (TTM) — earnings per share for the last 12 months, $: 7.42
Revenue QoQ — quarter-over-quarter revenue growth: -12.2%
EPS surprise: 6.3%
20d volatility: 1.7%
Dividend yield: 3.2%
last ex-date: 2026-06-15

AI recommendation changes

Date	Before	After	Reason
2026-10-11	Hold	Buy	Strong momentum and solid dividend yield support growth.
2026-10-03	Buy	Hold	Weak revenue growth offsets solid dividend yield.
2026-09-21	Hold	Buy	Solid fundamentals, but recent revenue decline raises concerns.
2026-09-14	Buy	Hold	Weak fundamentals and negative momentum raise concerns.
2026-09-06	Hold	Buy	Solid fundamentals, but recent revenue decline raises concerns.
2026-08-29	Buy	Hold	Mixed performance; cautious due to revenue decline.
2026-08-20	Hold	Buy	Strong momentum and solid dividend yield support growth.
2026-08-10	Sell	Hold	Mixed performance; cautious due to revenue decline.
2026-07-29	Hold	Sell	Mixed performance; cautious outlook amid revenue decline.
2026-07-21	Sell	Hold	Weak fundamentals and mixed momentum signal caution.
2026-07-13	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-06-17	Sell	Hold	Mixed performance; cautious outlook amid revenue decline.
2026-06-09	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-06-01	Buy	Hold	Weak fundamentals and mixed momentum signal caution.
2026-05-24	Hold	Buy	Mixed performance; cautious due to revenue decline.
2026-05-22	Sell	Hold	Weak fundamentals and negative momentum raise concerns.
2026-05-10	Hold	Sell	Weak fundamentals and negative momentum raise concerns.
2026-05-08	—	Hold	Stable earnings but mixed momentum and sector pressure.
2026-05-03	Hold	Buy	Компания демонстрирует стабильный рост выручки и дивидендную доходность, однако недавнее снижение цен акций и негативная динамика на более длительных сроках могут указывать на риски.
2026-04-25	Buy	Hold	Компания Gilead Sciences демонстрирует стабильный рост выручки и дивидендную доходность, однако недавние колебания цен акций и риск волатильности на рынке требуют осторожного подхода.
2026-03-30	Hold	Buy	Компания демонстрирует стабильный рост выручки и положительные показатели за последние 120 дней, что указывает на потенциал для дальнейшего роста. Дивидендная доходность также привлекательна, что делает акции интересными
2026-03-23	Buy	Hold	Компания демонстрирует стабильный рост выручки и дивидендную доходность, однако недавние колебания цен и снижение на коротких временных интервалах указывают на определенные риски.
2026-01-23	Hold	Buy	Компания Gilead Sciences демонстрирует положительную динамику цен на акции и имеет потенциал для роста благодаря своим инновационным продуктам в области здравоохранения. Низкий риск обусловлен стабильным спросом на лекар

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-10-23	Jefferies	Target Raised	— → 185	157.19
2026-10-12	Raymond James	Target Raised	— → 164	151.17
2026-10-08	RBC Capital	Target Raised	123 → 126	145.6366
2026-10-07	Truist Financial	Target Raised	150 → 158	147.53
2026-09-10	HSBC	Target Raised	155 → 175	145.65
2026-08-05	Truist Financial	Target Lowered	156 → 150	132.755
2026-08-05	RBC Capital	Target Raised	120 → 123	135.25
2026-07-29	Barclays	Target Lowered	155 → 145	134.32
2026-07-27	Morgan Stanley	Target Lowered	166 → 165	131.23
2026-07-20	Leerink Partners	Rating Downgraded	— → 127	133.21
2026-07-08	Morgan Stanley	Target Lowered	168 → 166	136.36
2026-07-07	RBC Capital	Target Lowered	122 → 120	129.61
2026-07-06	HSBC	Update	— → 155	131.27
2026-06-01	RBC Capital	Update	— → 122	134.43
2026-05-20	Maxim Group	Rating Upgraded	— → 165	130.5492
2026-05-10	Morgan Stanley	Target Lowered	175 → 168	131.33
2026-05-08	Truist Financial	Target Raised	155 → 157	132.025
2026-04-10	Morgan Stanley	Target Raised	171 → 175	140.34
2026-04-08	Truist Financial	Target Raised	152 → 155	141.54
2026-03-10	Jefferies	Update	— → 180	146.935
2026-02-19	Barclays	Update	— → 155	151.12
2026-02-19	Mizuho Securities	Target Raised	140 → 170	152.74
2026-02-18	UBS	Target Raised	155 → 175	155.27
2026-02-11	Scotiabank	Target Raised	140 → 177	155.29

News Page 1 of 1

Analysts JPMorgan highlight stocks poised to benefit from potential midterm election outcomes

10/05/2026, 10:37 AM investing forecast Analysts: analysts, JPMorgan finance Meta Platforms Oracle Gilead Sciences

JPMorgan analysts indicate that the upcoming U.S. midterm elections could significantly influence stock market dynamics, with different outcomes favoring specific sectors and companies. The potential for a split Congress or a Democratic majority presents distinct investment opportunities for investors to consider.

FDA Approves Gilead’s Daily HIV Pill Bixlenvo to Simplify Treatment for Patients

08/27/2026, 03:36 PM business announcement healthcare Gilead Sciences

Gilead's new HIV pill, Bixlenvo, has received FDA approval, offering a simplified treatment option for patients with controlled HIV who struggle with complex regimens. This development is significant as it addresses an unmet need in the HIV treatment landscape, potentially impacting patient adherence and overall health outcomes.

Court Ruling Against Importing Gilead Medications Impacts Alternative Funding Programs in the U.S.

08/14/2026, 09:38 AM business announcement Gilead Sciences

A recent court ruling in favor of Gilead Sciences could threaten the viability of alternative funding programs (AFPs) that import medications from abroad, potentially impacting drug accessibility for patients in the U.S.

Analysts Morgan Stanley recommend buying quality dividend-paying stocks amid market transition

07/28/2026, 12:36 PM investing recommendation Analysts: analysts, Morgan Stanley consumer finance Coca-Cola Colgate-Palmolive SLB Gilead Sciences

Morgan Stanley advises investors to focus on quality stocks as the market transitions, highlighting several dividend-paying companies that are expected to perform well amid current economic conditions.